庫潘尼西|T6322

價(jià)格	￥426	￥613	￥932
包裝	1mg	2mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:庫潘尼西	英文名稱:Copanlisib
CAS:1032568-63-0	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.88%	產(chǎn)品類別: 抑制劑
貨號: T6322

Product Introduction

Bioactivity

名稱	Copanlisib
描述	Copanlisib (BAY 80-6946) is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
細(xì)胞實(shí)驗(yàn)	Cell proliferation over a 72-hour period is determined using the CellTiter-Glo? luminescent cell viability kit. Briefly, cells are plated in separate microtiter plates. Following an overnight incubation at 37oC, luminescence values in the t=0 hour plates are determined. Test compounds diluted in growth medium are added to the t=72 hour plates, and the cells are then incubated for 72 hours at 37oC. Luminescence values are determined with a Wallac 1420 Victor2? 1420 multilabel HTS counter after a 10-minute reaction with CellTiter-Glo? solution. The percentage inhibition of cell growth is calculated by subtracting the luminescence values in the t=0 hour plates from the corresponding values in the t=72 hour plates. Differences in values between drug-treated cells and controls are used to determine the percentage inhibition of cell growth.(Only for Reference)
激酶實(shí)驗(yàn)	Biochemical lipid kinase assays: The effect of BAY 80-6946 on PI3Kα, PI3Kβ, and PI3Kγ activity is measured by the inhibition of 33P incorporation into phosphatidylinositol (PI) in 384-well MaxiSorp? plates coated with 2 μg/well of PI and phosphatidylserine (PS) (1:1 molar ratio). In each PI3K isoform assay, 9 μL of reaction buffer (50 mM MOPSO, pH 7.0, 100 mM NaCl, 4 mM MgCl2, 0.1% BSA) containing 7.5 ng of His-tagged N-terminal truncated p110α or p110β protein, or 25 ng of purified human p110γ protein, is used. The reaction is started by adding 5 μL of a 40-μM ATP solution containing 20 μCi/mL [33>/sup>P]-ATP. After 2 hours incubation at room temperature, the reaction is terminated by addition of 5 μL of a 25-mM EDTA solution. The plates are washed and Ultima Gold? scintillation cocktail (25 μL) is then added. The radioactivity incorporated into the immobilized PI substrate is determined with a BetaPlate Liquid Scintillation Counter.
體外活性	在KPL4細(xì)胞和LPA刺激的PC3細(xì)胞中，Copanlisib降低pAKT水平。在一組存在PIK3CA突變和/或HER2過表達(dá)的人類癌癥細(xì)胞系中，Copanlisib展示了抗增殖活性并誘導(dǎo)了凋亡。[1] HER2靶向療法與Copanlisib的聯(lián)合應(yīng)用比單獨(dú)使用任一療法更有效地抑制增長，并能在細(xì)胞中恢復(fù)對trastuzumab和lapatinib的敏感性。[2]
體內(nèi)活性	在大鼠KPL4或HCT116腫瘤異種移植模型中，Copanlisib（6 mg/kg，靜脈注射）可誘導(dǎo)100%的完全腫瘤消退。在攜帶Lu7860厄洛替尼耐藥、源自患者的非小細(xì)胞肺癌和MAXF1398源自患者的腺泡狀乳腺腫瘤模型的裸鼠中，Copanlisib（14 mg/kg，靜脈注射）同樣可抑制腫瘤生長。[1]
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : < 1 mg/mL (insoluble or slightly soluble) H2O : Insoluble 0.01M HCl : 10 mg/mL (20.81 mM), Sonication is recommended.
關(guān)鍵字	PI3K \| Apoptosis \| antiproliferative \| antitumor \| Inhibitor \| administration \| phosphorylation \| sub-nanomolar \| AKT \| Phosphoinositide 3-kinase \| inhibit \| Copanlisib \| intravenous
相關(guān)產(chǎn)品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相關(guān)庫	抗癌上市藥物庫 \| 經(jīng)典已知活性庫 \| 抗癌活性化合物庫 \| 抗衰老化合物庫 \| FDA 上市藥物庫 \| 藥物功能重定位化合物庫 \| 抗癌藥物庫

關(guān)鍵字：庫潘尼西|||可泮利塞|||BAY 80-6946|TargetMol

公司簡介

上海陶術(shù)生物科技有限公司為美國Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國波士頓、德國慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個性化定制合成；從對明確靶點(diǎn)的分子篩選到對明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過在中國市場五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊資本	566.2651萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊資本：566.2651萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑，藥物篩選化合物庫，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場三路28號4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

成藥庫

￥5000

農(nóng)藥庫

￥5000

靶點(diǎn)庫

￥5000